We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy.
- Authors
Calvo, D. B.; Patt, Y. Z.; Wallace, S.; Chuang, V. P.; Benjamin, R. S.; Pritchard, J. D.; Hersh, E. M.; Bodey, G. P.; Mavligit, G. M.; Calvo, D B 3rd; Bodey, G P Sr
- Abstract
Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.
- Subjects
HEARING; RESEARCH; LIVER tumors; CLINICAL drug trials; NEUROBLASTOMA; KIDNEYS; CLINICAL trials; MELANOMA; RESEARCH methodology; PERIPHERAL nervous system; EVALUATION research; MEDICAL cooperation; COMPARATIVE studies; CISPLATIN; BONE marrow; SARCOMA; BREAST tumors; INTRA-arterial infusions
- Publication
Cancer (0008543X), 1980, Vol 45, Issue 6, p1278
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19800315)45:6<1278::AID-CNCR2820450603>3.0.CO;2-I